磷霉素对比环丙沙星作为女性大肠埃希菌发热性尿路感染口服降阶梯治疗:一项随机、安慰剂对照、双盲、多中心试验
在15家荷兰医院开展的随机双盲安慰剂对照试验中,97例接受2-5天静脉抗菌药物经验治疗的成年女性大肠埃希菌发热性尿路感染患者,被分配接受磷霉素每日3g一次或环丙沙星每日0.5g两次口服降阶梯治疗,总抗生素疗程10天。因COVID-19疫情试验提前终止,磷霉素组与环丙沙星组临床治愈率分别为75.0%和65.2%(RD 9.6%,95%CI -8.8%至28.0%),磷霉素非劣效于环丙沙星,但胃肠道不良事件更多。
要点
- 磷霉素组临床治愈36/48(75.0%),环丙沙星组30/46(65.2%),RD 9.6%(95%CI -8.8%至28.0%)。
- 微生物学治愈磷霉素组29/37(78.4%)低于环丙沙星组33/35(94.3%),RD -16.2%(95%CI -32.7至-0.0)。
- 胃肠道不良事件磷霉素组25/48(52.1%)高于环丙沙星组14/46(30.4%),RD 20.8%(95%CI 1.6%至40.0%)。
核心结论
- 磷霉素作为女性大肠埃希菌发热性尿路感染的口服降阶梯治疗非劣效于环丙沙星。
- 磷霉素使用与更多胃肠道事件相关。
研究设计与样本
- 双盲、随机、安慰剂对照试验,在15家荷兰医院开展。
- 成年女性接受2-5天静脉抗菌药物经验治疗的大肠埃希菌发热性尿路感染患者入组。
- 分配到磷霉素每日3g一次或环丙沙星每日0.5g两次口服降阶梯治疗,总抗生素疗程10天。
- 主要终点为治疗结束后第6-10天(PET)临床治愈,非劣效界值10%。
- 2017年至2020年间入组97例后,因COVID-19疫情试验提前终止。
主要发现
- 主要终点磷霉素组48例中36例(75.0%)达到,环丙沙星组46例中30例(65.2%)达到,RD 9.6%(95%CI -8.8%至28.0%)。
- 微生物学治愈在PET第6-10天磷霉素组37例中29例(78.4%),环丙沙星组35例中33例(94.3%),RD -16.2%(95%CI -32.7至-0.0%)。
- 任何胃肠道不良事件磷霉素组48例中25例(52.1%),环丙沙星组46例中14例(30.4%),RD 20.8%(95%CI 1.6%至40.0%)。
关键数值与推荐
- 非劣效界值设定为10%。
- 临床治愈定义为治疗结束后第6-10天(PET)达到临床治愈。
临床怎么用
- 作者结论认为磷霉素作为女性大肠埃希菌发热性尿路感染的口服降阶梯治疗非劣效于环丙沙星。
- 作者指出磷霉素使用与更多胃肠道事件相关。
局限性
- 因COVID-19疫情,入组97例后试验提前终止。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to determine the noninferiority of fosfomycin compared to ciprofloxacin as an oral step-down treatment for Escherichia coli febrile urinary tract infections (fUTIs) in women. METHODS: This was a double-blind, randomized, controlled trial in 15 Dutch hospitals. Adult women who were receiving 2-5 days of empirical intravenous antimicrobials for E. coli fUTI were assigned to step-down treatment with once-daily 3g fosfomycin or twice-daily 0.5g ciprofloxacin for 10 days of total antibiotic treatment. For the primary end point, clinical cure at days 6-10 post-end of treatment (PET), a noninferiority margin of 10% was chosen. The trial was registered on Trialregister.nl (NTR6449). RESULTS: After enrollment of 97 patients between 2017 and 2020, the trial ended prematurely because of the coronavirus disease 2019 pandemic. The primary end point was met in 36 of 48 patients (75.0%) assigned to fosfomycin and 30 of 46 patients (65.2%) assigned to ciprofloxacin (risk difference [RD], 9.6%; 95% confidence interval [CI]: -8.8% to 28.0%). In patients assigned to fosfomycin and ciprofloxacin, microbiological cure at days 6-10 PET occurred in 29 of 37 (78.4%) and 33 of 35 (94.3%; RD, -16.2%; 95% CI: -32.7 to -0.0%). Any gastrointestinal adverse event was reported in 25 of 48 (52.1%) and 14 of 46 (30.4%) patients (RD, 20.8%; 95% CI: 1.6% to 40.0%), respectively. CONCLUSIONS: Fosfomycin is noninferior to ciprofloxacin as oral step-down treatment for fUTI caused by E. coli in women. Fosfomycin use is associated with more gastrointestinal events. CLINICAL TRIAL REGISTRATION: Trial NL6275 (NTR6449).
引用
- Ten Doesschate T, Kuiper S, van Nieuwkoop C, et al. Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Clin Infect Dis. 2022. PMID: 34791074. doi:10.1093/cid/ciab934
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。